**Clostridium butyricum** MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8

MASAHI Hide SHINNOH1,2*, MANO HORINAKA1*, TAKASHI YASUDA1,2, SAE YOSHIKAWA1, MIE MORITA1, TAKESHI YAMADA1,2, TSUNEHARU MIKI2 and TOSHIYUKI SAKAI1

Departments of 1Molecular-Targeting Cancer Prevention and 2Urology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyō-ku, Kyoto 602-8566, Japan

Received November 2, 2012; Accepted December 14, 2012

DOI: 10.3892/ijo.2013.1790

**Abstract.** Bacillus Calmette-Guérin (BCG) intravesical therapy against superficial bladder cancer is one of the most successful immunotherapies in cancer, though the precise mechanism has not been clarified. Recent studies have demonstrated urinary tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels to be higher in BCG-responsive patients than non-responders and shown that polymorphonuclear neutrophils (PMNs) migrating to the bladder after BCG instillation release large amounts of TRAIL. To establish a safer and more effective intravesical therapy than BCG, we examined whether other bacteria induced similar effects. We stimulated PMNs or peripheral blood mononuclear cells (PBMCs) with BCG or other bacteria, and then aliquots of the culture supernatants or cell lysates were assayed for TRAIL. We examined the signaling pathway regulating the release of TRAIL from PMNs and evaluated the antitumor effects of BCG or other bacteria in vitro and in vivo. We have found that *Clostridium butyricum* MIYAIRI 588 (CBM588) induces the release of endogenous TRAIL from PMNs as well as BCG. In addition, we have shown that matrix metalloproteinase 8 (MMP-8) is one of the key factors responsible for the release. Interestingly, TLR2/4 signaling pathway has been suggested to be important for the release of TRAIL by MMP-8. CBM588 has been proven to be as effective as BCG against cancer cells by inducing apoptosis in vivo as well as in vitro. Taken together, these results strongly suggest that CBM588 is promising for a safer and more effective therapy against bladder cancer.

**Introduction**

Bladder cancer is one of the most common malignant tumors in the United States (1). Approximately 70% of newly diagnosed bladder cancers are of the superficial type (2). A mainstay of therapy for superficial bladder cancer is complete transurethral resection. However, bladder cancer locally relapses in 70% of patients, and progresses to muscle invasive cancer after transurethral resection in 30%. To reduce this recurrence and progression, intravesical instillation of antitumor agents has been used since the early seventies (3).

*Bacillus Calmette-Guérin* (BCG) was isolated from *Mycobacterium bovis* which caused bovine tuberculosis in 1921 (4). Since the intravesical instillation of BCG for bladder cancer therapy was first reported in 1976 (5), it has become the most successful immunotherapy for non-invasive bladder cancer (6). However, the instillation of BCG has serious side effects, such as disseminated infections, sepsis and multiple organ failure (7,8). Therefore, the discovery of other bacteria which have the same anticancer effects with less side effects is required for bladder cancer patients. Indeed, intravesical treatments with other bacteria have been reported (9,10).

Although BCG intravesical therapy is one of the most successful immunotherapies, its precise mechanism is still unknown. Recently, it has been reported that the concentration of urinary tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was higher in BCG-responsive patients than non-responders (11). Furthermore, polymorphonuclear neutrophils (PMNs) migrating to the bladder after BCG instillation release large amounts of TRAIL (12). TRAIL is a cytokine inducing apoptosis in malignant tumor cells without affecting normal cells (13-15) and is considered a promising anticancer agent in clinical trials (16,17).

It has been reported that matrix metalloproteinases (MMPs) stimulate the release of cytokines and chemokines via proteolytic processing (18-20). Other proteases, such as a disintegrin and metalloproteases (ADAMs) or cathepsin E, have been also reported to be required for shedding of cyto-

---

**Correspondence to:** Dr Toshiyuki Sakai, Department of Molecular-Targeting Cancer Prevention, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyō-ku, Kyoto 602-8566, Japan

E-mail: tsakai@koto.kpu-m.ac.jp

*Contributed equally

**Abbreviations:** CBM588, Clostridium butyricum MIYAIRI 588; BCG, Bacillus Calmette-Guérin; PMN, polymorphonuclear neutrophil; PBMC, peripheral blood mononuclear cell; MMP, matrix metalloproteinase; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TLR, toll-like receptor

**Key words:** *Clostridium butyricum* MIYAIRI 588, BCG, bladder cancer, TRAIL, MMP-8
kines from the cell surface (21,22). However, little is known about the mechanism of TRAIL release in PMNs (23).

In this study, we have found that *Clostridium butyricum* MIYAIRI 588 (CBM588) induces the release of TRAIL from PMNs, resulting in marked anticancer effects in vitro and in vivo. We have additionally found that MMP-8 is one of the key molecules for TRAIL release. We therefore hypothesize that CBM588 might be useful for a novel intravesical therapy against bladder cancer.

**Materials and methods**

**Reagents.** *Clostridium butyricum* MIYAIRI 588 (Miyarisan Pharma., Tokyo, Japan), BCG (Nippon Kayaku, Tokyo, Japan and Sanofi-Aventis, Tokyo, Japan), *Lactobacillus casei* (Yakult, Tokyo, Japan), Krestin (Daichi Sankyo, Tokyo, Japan), Lentinan (Astellas Pharma, Tokyo, Japan) and IFN-α (Dainippon Sumitomo Pharma, Osaka, Japan) were dissolved in PBS. S.7-oxozaenal (Chugai Pharma., Tokyo, Japan), SB203580, SP600125 (Jena Bioscience, Jena, Germany), cathepsin G inhibitor (Santa Cruz Biotechnology, Santa Cruz, CA, USA), MMP-8 inhibitor and MMP-9 inhibitor (Merck, Darmstadt, Germany) were dissolved in dimethyl sulfoxide (DMSO). Cycloheximide, leupeptin and EDTA were purchased from Nacalai Tesque (Kyoto, Japan). Human recombinant DR5/Fc chimera and zVAD-fmk were obtained from R&D Systems (Minneapolis, MN, USA). Actinomycin D and 1,10-phenanthroline were obtained from Sigma (St. Louis, MO, USA). Anti-human TLR2 and TLR4 were purchased from eBioscience (San Diego, CA, USA).

**Cell culture.** Human bladder cancer 253J-BV cells (24) provided by Dr K. Inoue (University of Kochi), human lung cancer H460, human renal cancer 786-O, human embryonic kidney HEK293 and murine bladder cancer MBT-2 cell lines were maintained in RPMI-1640 medium with 10% fetal bovine serum (FBS), 2 mM glutamine and 100 µg/ml streptomycin. Normal PMNs were isolated using Polymorphprep (Axis-Shield, Oslo, Norway) and normal PBMCs were isolated using Lymphoprep (Axis-Shield, Oslo, Norway) and normal PBMCs were acquired from healthy volunteers after obtaining informed consent. This study was approved by the Kyoto Prefectural University of Medicine Research Ethics Committee (permission no. C-425 and C-919). All cell lines except 253J-BV used in this study were obtained from American Type Culture Collection (ATCC).

**Sequence analysis.** The transmembrane domain of TRAIL was calculated using version 2.0 of TMHMM (http://www.cbs.dtu.dk/services/TMHMM/). SignalP (http://www.cbs.dtu.dk/services/SignalP/) was used for the prediction of signal peptides.

**Generation of mutations in the transmembrane domain of TRAIL.** Two constructs were generated, replacing the transmembrane domain of TRAIL using a site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The first mutant construct (MT1) was obtained by substitution of the TRAIL transmembrane domain (residues 32-33: Ala-Val) with the peptide sequence (Ala-Asp). The second mutant (MT2) was replaced with the peptide sequence (Glu-Val).

**Enzyme-linked immunosorbent assay (ELISA).** PMNs (2.5x10⁶/ml) were incubated in the presence or absence of CBM588, BCG, or other reagents for 6 h. PMNs were centrifuged and the supernatant was collected. A human TRAIL ELISA kit (Abcam, Cambridge, UK) was used according to the manufacturer's instructions.

**RNA isolation and quantification by real-time reverse transcription-PCR.** RNA isolation and quantitative real-time RT-PCR were carried out as described (25). The real-time quantitative reverse transcription-PCR primer-probe sets for TRAIL mRNA (Hs00234355_m1) and GAPDH mRNA (Hs99999905_m1) were purchased from Applied Biosystems (Foster City, CA, USA).

**Western blot analysis.** Western blot analysis was carried out as described previously (25). Rabbit polyclonal MMP-8 (Chemicon, Temecula, CA, USA), MMP-9 (Abcam), caspase-3, and mouse specific caspase-8 (Cell Signaling Technology, Beverly, MA, USA) antibodies, and mouse monoclonal human TRAIL (Santa Cruz Biotechnology) and β-actin (Sigma) antibodies were used as the primary antibodies.

**Stable transfection and siRNA transfection.** The human TRAIL expression plasmid pCAGGS NEO-TRAIL was described previously (26). 786-O cells and HEK293 cells were transfected with pCAGGS NEO-TRAIL or pCAGGS NEO, a vacant vector plasmid, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Transfected cells were selected in growth medium with 1 mg/ml G418 (Sigma) and kept stable for more than 1 month before experiments.

**siRNAs were transfected** using Lipofectamine RNAiMax Reagent (Invitrogen) according to the manufacturer's instructions. Briefly, 1x10⁶ cells were seeded into 6-well tissue culture plates 1 day before transfection with 50 nM MMP-8 siRNA (Hs00233972_m1), MMP-9 siRNA (Hs00234579_m1), or a control siRNA (Silencer Select Negative Control #2 siRNA) (Ambion, Austin, TX, USA). After 48 h, we analyzed the culture medium of transfected cells by western blotting to evaluate the release of soluble TRAIL.

**Implantation of MBT-2 cells into C3H/HeN mice and the protocol in vivo.** C3H/HeN female mice were obtained from Shimizu Laboratory Supplies (Kyoto, Japan). The present study complied with the principles and guidelines of the Japanese Council on Animal Care and it was also approved by the Committee for Animal Research of Kyoto Prefectural University of Medicine (permisson no. M23-180). MBT-2
cells were harvested and resuspended in 1:1 PBS/Matrigel mixture. Cells (2\times10^5) in 100 µl of mixture were injected s.c. into both flanks of each mouse. Mice were randomized into the following treatment groups (n=3): group I, untreated control (PBS, 100 µl/tumor); group II, CBM588 (0.2 mg/tumor); and group III, BCG (0.4 mg/tumor), once weekly, intratumor injection. Therapy was continued for 31 days. Tumor dimensions were measured with vernier calipers. Tumor volume was calculated using the formula: (shortest diameter)^2 \times (longest diameter) /2. Tumor volume was compared among groups using an unpaired Student’s t-test.

Results

Clostridium butyricum MIYAIRI 588 (CBM588) enhances the release of TRAIL from PMNs. It has been reported that BCG stimulates the release of TRAIL from PMNs (12). We then evaluated whether other bacteria have similar effects. We added BCG, CBM588, Lactobacillus casei, Krestin, Lentinan (each 10 µg/ml) or IFN-α (1,000 IU/ml) for 6 h. All bacteria were sterilized by heating. **P<0.01 versus PBS. PMNs were stimulated with CBM588 at the doses indicated for 6 h. *P<0.01 versus PBS. PMNs were stimulated with CBM588 (50 µg/ml) for the period indicated. **P<0.01 versus PBS. PMNs were isolated from different plural donors. Each donor's PMNs were stimulated with PBS or CBM588 (50 µg/ml) for 6 h. **P<0.01 versus each donor's CBM588 (-). PMNs were isolated from different plural donors. Each donor's PMNs were stimulated with PBS or CBM588 (50 µg/ml) for 6 h. **P<0.01 versus PBS. Columns, mean; bars, mean ± SD.
Shinoh et al.: *Clostridium butyricum* shows antitumor effects

Soluble TRAIL was drastically induced by CBM588 at 10 µg/ml or more (Fig. 1B) and time-dependently induced by 50 µg/ml of CBM588 (50 µg/ml) or BCG (100 µg/ml) for 6 h. (A) Total RNA was isolated from PMNs and TRAIL mRNA levels were quantified by real-time PCR. (B) Isolated PMNs were lysed and TRAIL was detected by western blotting. (C) PMNs (2.5x10^6 cells/ml) were treated with cycloheximide (CHX; 10 µg/ml) or actinomycin D (ActD; 1 µg/ml) for 1 h before stimulation with CBM588 (50 µg/ml). TRAIL levels in the culture supernatant at 1, 3 and 6 h after CBM588 was added were measured by ELISA. Columns, mean; bars, mean ± SD.

CBM588, similarly to BCG, does not induce TRAIL synthesis but stimulates the release of TRAIL from intracellular stores in PMNs. Kemp (12) reported that BCG did not increase TRAIL mRNA levels in PMNs and we have found that BCG or CBM588 did not induce TRAIL mRNA expression, whereas IFN-α did (Fig. 2A). We additionally evaluated the expression of the TRAIL protein in PMNs by western blotting. The amount of the protein was increased by IFN-α, whereas it was decreased by CBM588 or BCG (Fig. 2B). Furthermore, to determine whether CBM588 or BCG induces de novo synthesis of TRAIL in PMNs, we treated PMNs with a protein or RNA synthesis inhibitor, cycloheximide (10 µg/ml) or actinomycin D (1 µg/ml), respectively, for 1 h before adding CBM588 or BCG. The inhibitors did not suppress the release of TRAIL from PMNs (Fig. 2C). These results suggest that PMNs possess intracellular stores of TRAIL and that CBM588 or BCG induces the release of TRAIL from these stores without inducing TRAIL synthesis.

CBM588, similarly to BCG, does not induce TRAIL synthesis but stimulates the release of TRAIL from intracellular stores in PMNs. Kemp (12) reported that BCG did not increase TRAIL mRNA levels in PMNs and we have found that BCG or CBM588 did not induce TRAIL mRNA expression, whereas IFN-α did (Fig. 2A). We additionally evaluated the expression of the TRAIL protein in PMNs by western blotting. The amount of the protein was increased by IFN-α, whereas it was decreased by CBM588 or BCG (Fig. 2B). Furthermore, to determine whether CBM588 or BCG induces de novo synthesis of TRAIL in PMNs, we treated PMNs with a protein or RNA synthesis inhibitor, cycloheximide (10 µg/ml) or actinomycin D (1 µg/ml), respectively, for 1 h before adding CBM588 or BCG. The inhibitors did not suppress the release of TRAIL from PMNs (Fig. 2C). These results suggest that PMNs possess intracellular stores of TRAIL and that CBM588 or BCG induces the release of TRAIL from these stores without inducing TRAIL synthesis.
CBM588 induces the release of TRAIL from PMNs through the TLR2/4 signaling pathway. Toll-like receptors (TLRs) play a role in mediating innate immune reactions (29,30) and TLR2 and TLR4 have been reported to be involved in the host immune response to BCG (31,32). Therefore, we evaluated whether TLR2 or TLR4 was associated with TRAIL release from PMNs by CBM588 or BCG. We stimulated PMNs with CBM588 or BCG for 6 h after incubating with TLR2 or TLR4 neutralization antibody for 0.5 h and then measured concentrations of soluble TRAIL using ELISA. TLR2 or TLR4 neutralization antibody inhibited the release of TRAIL by CBM588 or BCG (Fig. 3A and B). Inhibition of the downstream pathway of TLR2 or TLR4 by a TAK1 inhibitor 5Z-7-oxozeaenol (33), a p38 MAPK inhibitor SB203580 and a JNK inhibitor SP600125 suppressed the release of TRAIL by CBM588 (Fig. 3C). CBM588 or BCG upregulated the phosphorylation of p38 and JNK in PMNs (data not shown). These results strongly suggest that CBM588 or BCG releases TRAIL from PMNs at least partially through a TLR2 or TLR4 signaling pathway.

MMP-8 is one of the key molecules for the release of TRAIL from PMNs. To determine what protease was associated with the release of TRAIL from PMNs, we examined whether protease inhibitors suppressed the release. Among the inhibitors examined, general MMP inhibitors, such as 1,10-phenanthroline and EDTA, markedly decreased the concentration of soluble TRAIL in the culture supernatant of PMNs stimulated by CBM588 or BCG (Fig. 4A and B), while the cathepsin G inhibitor had only a slight effect. PMNs are known to have abundant MMP-8 and -9, and therefore we examined the effect of an MMP-8 or -9 specific inhibitor on the release of TRAIL by CBM588. As shown in Fig. 4C, the MMP-8 specific inhibitor suppressed the accelerated release of TRAIL by CBM588, whereas the MMP-9 specific inhibitor only weakly inhibited the release. When PMNs are activated, MMPs are released from their granules to the extracellular area (34-36). We therefore detected MMP-8 and -9 in culture supernatant by western blotting and found that CBM588 drastically increased MMP-8 and -9 protein levels. Whereas the MMP-8 level was decreased by 5Z-7-oxozeaenol, SB203580 or SP600125, the level of MMP-9 was not changed (Fig. 4D). These results suggest that MMP-8 at least partially releases TRAIL and is regulated by TLR2/4 downstream signaling.

We next examined the effects of MMP-8/9 siRNA on the release of TRAIL. We transfected the TRAIL expression vector into TRAIL-resistant human renal cancer 786-O cells, and established a stable TRAIL-expressing cell line. Subsequently, we transiently transfected MMP-8 siRNA or MMP-9 siRNA into this cell line. As shown in Fig. 4E, knockdown of MMP-8, but not MMP-9, decreased TRAIL levels in the culture supernatant. Therefore, this result strongly suggests that MMP-8 is crucial to the release of TRAIL. Fig. 4F shows the amino acid sequence of human TRAIL, including a putative transmembrane domain identified using TMHMM. Using SignalP 3.0, we found a proteolytic cleavage site of TRAIL, which could be digested by MMP-8 and -9. We constructed plasmids with a mutation at this site, and named them MT1 and MT2 (Fig. 4G). As shown in Fig. 4H, the introduction of a mutation at the putative proteolytic cleavage site remarkably inhibited the release of TRAIL from TRAIL-expressing HEK293 cells. Therefore, these results clearly show that the site is absolutely necessary for the release of TRAIL and that MMP-8 is a candidate for the proteolytic enzyme of TRAIL.

Release of TRAIL from PMNs stimulated by CBM588 results in the apoptosis of human cancer cells in vitro. A recent study demonstrated that BCG enhanced the cytotoxicity of PMNs against bladder cancer cells (37). We then added CBM588 to PMNs, and found that the supernatant drastically enhanced the apoptosis of human lung cancer H460 cells (Fig. 5A). The pan-caspase inhibitor zVAD-fmk inhibited apoptosis, while a dominant negative protein against DR5, the DR5/Fc chimera, partially inhibited it (Fig. 5A). We also confirmed the results by crystal violet staining, and found that CBM588 alone had little effect on cancer cell death (data not shown). We performed the next experiment using bladder cancer 253J-BV cells and found that apoptosis was similarly induced by PMNs with CBM588 and inhibited by zVAD-fmk or 5Z-7-oxozeaenol, a TAK1 inhibitor (Fig. 5B). These results suggest that TRAIL released from PMNs by CBM588 induces caspase-dependent apoptosis of cancer cells.

CBM588 suppresses the growth of murine bladder cancer cells in C3H/HeN mice. Previous studies showed that BCG induced antitumor effects against bladder cancer cells in vivo (37,38). We then examined the effects of CBM588 and BCG against murine bladder cancer MBT-2 cells inoculated in C3H/HeN mice. As shown in Fig. 6A, on day 0, MBT-2 cells were subcutaneously inoculated into both flanks of mice. On days 3, 10, 17 and 24, CBM588, BCG or PBS as a control was injected into each tumor. The tumor volume was measured by vernier calipers on each day indicated. A significant difference in weight was not observed among the three groups (Fig. 6B). Intratumor injection of BCG partially suppressed tumor growth, while CBM588 almost completely inhibited it (Fig. 6C). We additionally evaluated the activation of caspase-8 and -3 in tumor cell lysate by western blotting. We detected the cleaved form of caspase-8 and -3 from lysate of tumors treated with CBM588 or BCG (Fig. 6D). These results suggest that CBM588 is also useful in vivo to suppress the growth of bladder cancer cells.

Discussion

BCG is recognized as one of the most effective agents against superficial bladder cancer. Despite great effort, however, the serious side effects of BCG, such as disseminated infections, sepsis, and multiple organ failure (7,8) have yet to be eliminated. In addition, the best use of BCG has not been clearly determined, because of a poor understanding of its mechanisms of action. It is therefore necessary to clarify the antitumor mechanisms of BCG for safer and more effective use.

In the present study, we found that the non-toxic and harmless Clostridium, CBM588, drastically suppressed the growth of bladder cancer cells in vitro and in vivo. CBM588 is known to be a component of intestinal bacterial flora. This strain has been shown to be non-toxic and harmless unlike other Clostridium and is commonly used as a probiotic for diarrhea.
Therefore, CBM588 is promising for the novel and safer treatment of superficial bladder cancer.

We found that CBM588 as well as BCG induced the release of TRAIL from intracellular stores in PMNs, while they did not enhance TRAIL synthesis. On the other hand, it has been reported that a combination of intravesical BCG with IFN-α was effective (40,41). IFN-α upregulates the transcription of TRAIL in PMNs (12) and therefore it might be more effective for CBM588 intravesical therapy to use IFN-α. Furthermore, CBM588 shows promise in combina-
tion with various agents enhancing sensitivity to TRAIL, such as inducers of a TRAIL receptor, death receptor (DR) 5. We previously reported a variety of agents upregulating DR5 expression (25, 42, 43). Among them, sulforaphane in broccoli sprouts might be useful in combination with the intravesical CBM588 therapy, because of its own antitumor effects (44) and effective transition to urine (45).

The proteolytic activities of various proteases, such as lysosomal cathepsins and MMPs, have been associated with many malignant tumors (46, 47). However, several strategies designed to broadly block MMPs have not been successful as cancer therapy, perhaps due to their functional diversity in vivo (48, 49). For example, several MMPs, such as MMP-3, -8 and -12, were found to have antitumorigenic effects through the suppression of tumor angiogenesis and degradation of chemokines that mediate organ-specific metastasis (47). In the present study, we demonstrated that MMP-8 induced the release of TRAIL, consistent with the hypothesis described above.

In conclusion, we have found that CBM588 is safer than BCG and effective against human bladder cancer cells in vitro.

![Figure 5](image1.png)

Figure 5. Release of TRAIL from PMNs stimulated by CBM588 results in the apoptosis of human cancer cells in vitro. (A and B) PMNs (5.0x10^6 cells/ml) were incubated with or without CBM588, DR5/Fc chimera, zVAD-fmk or 5Z-7-oxozaenol for 24 h. After centrifugation, the culture supernatant was collected and added to lung cancer H460 cells (2.5x10^5 cells/ml) (A), or bladder cancer 253J-BV cells (2.5x10^5 cells/ml) (B). After 48 h, apoptosis was analyzed by flow cytometry. *P<0.01 versus PMNs with CBM588. Columns, mean; bars, mean ± SD.

![Figure 6](image2.png)

Figure 6. CBM588 suppresses the growth of murine bladder cancer cells in C3H/HeN mice. (A) Schematic representation of the experimental protocol described in Materials and methods. Animals were divided into 3 groups (n=3). Group I was treated with PBS (100 µl/tumor), group II was treated with CBM588 (0.2 mg/tumor) and group III was treated with BCG (0.4 mg/tumor). (B) The change of murine body weight in each group. (C) The tumor volume of each mouse was measured on the days indicated. *P<0.01 versus PBS. (D) Isolated murine tumors were lysed, and caspase-8 and -3 were detected by western blotting. Columns, mean; bars, mean ± SD.
and in vivo. We additionally clarified that TRAIL release by CBM588 is important for the antitumor effect and that MMP-8 is one of the key molecules responsible for the release. We believe that this discovery will lead to a novel intravesical therapy for bladder cancer.

Acknowledgments

The authors thank Drs K. Inoue and C.P. Dinney for generously providing the human bladder cancer cell line 253J-BV and Dr T. Yoshida for helpful discussions. The gifts of Clostridium butyricum MYI AIRI 588 from Miyarisan Pharmaceutical, BCG from Nippon Kayaku and Sanofi-Aventis Pharmaceutical, and 5Z-7-oxozeanol from Chugai Pharmaceutical are gratefully acknowledged. This study was partly supported by the Japanese Ministry of Education, Culture, Sports, Science and Technology (22790547 to M. Horinaka).

References


